726 related articles for article (PubMed ID: 26303211)
1. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Vidula N; Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
3. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Hecht KA; Selby C
Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
6. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
8. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
11. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
12. Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
Xu H; Yu S; Liu Q; Yuan X; Mani S; Pestell RG; Wu K
J Hematol Oncol; 2017 Apr; 10(1):97. PubMed ID: 28438180
[TBL] [Abstract][Full Text] [Related]
13. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
14. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
16. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
18. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
19. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
20. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]